Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
  • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
  • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/11—Antisense
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/30—Chemical structure
  • C12N2310/34—Spatial arrangement of the modifications
  • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/30—Chemical structure
  • C12N2310/35—Nature of the modification
  • C12N2310/351—Conjugate
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2320/00—Applications; Uses
  • C12N2320/30—Special therapeutic applications
  • C12N2320/31—Combination therapy

Definitions

• RNAi agent comprising: an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:8 and SEQ ID NO:9, and a complementary sense strand.
• the complementary sense strand comprises a nucleotide sequence of any one of the following: SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.
• the disclosure provides methods of treating a Hepatitis B viral (HBV) infection in a subject with severe renal impairment or end-stage renal disease (ESRD), comprising administering an RNAi component as set forth above.
• HBV Hepatitis B viral
• ESRD end-stage renal disease
• the subject is also undergoing dialysis.
• the subject with severe renal impairment or ESRD is also hepatically impaired.
• the subject has ESRD, is undergoing dialysis and is hepatically impaired.
• the subject has ESRD, is not undergoing dialysis and is hepatically impaired.
• the disclosure provides methods of treating HBV in a renally impaired subject, said method comprising subcutaneously administering to the subject a pharmaceutical composition comprising an RNAi component comprising
• a first RNAi agent comprising: an antisense strand comprising a nucleotide sequence of SEQ ID NO:2 and a complementary sense strand (e.g., a sense strand comprising a nucleotide sequence of SEQ ID NO: 11); and
• the first RNAi comprises an antisense strand comprising a nucleotide sequence that is at least 90% homologous to SEQ ID NO: 2 and a complementary sense strand comprising a nucleotide sequence that is at least 90% homologous to SEQ ID NO: 11
• the second RNAi comprises an antisense strand comprising a nucleotide sequence that is at least 90% homologous to SEQ ID NO:8 and a complementary sense strand comprising a nucleotide sequence that is at least 90% homologous to SEQ ID NO: 16.
• the RNAi component are administered to the subject over the same treatment period for up to 2 years, up to 1 year, up to 6 months, or up to any time of 1 month to 2 years.
• the treatment comprises a first phase conducted before a second phase, and a) the first phase comprises administering the RNAi component to the subject to thereby decrease the HBsAg to a level low enough to allow recovery of T cell function, preferably to a serum HBsAg level of less than 1000, 100, 10, or 1 IU/mL; and b) the second phase comprises administering an additional compound or drug effective for treating hepatitis infection.
• the term “pharmaceutically acceptable salt” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
• pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
• the pharmaceutically acceptable salts provided herein include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
• the pharmaceutically acceptable salts provided herein can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
• HBV infections that may be treated according to the disclosed methods include HBV genotype A, B, C, and/or D infections.
• the methods disclosed may treat any HBV genotype (“pan-genotypic treatment”).
• HBV genotyping may be performed using methods known in the art, for example, INNO-LIPA® HBV Genotyping, Innogenetics N.V., Ghent, Belgium).
• the level of renal sufficiency in an individual can also be determined for the first time when the individual visits the health care practitioner.
• an individual is asked orally or in writing a series of questions to determine the individual's level of renal sufficiency. Questions can include asking about risk factors that are related to renal sufficiency. Risk factors relevant to an individual's level of renal sufficiency include, for example, does the individual have diabetes, high blood pressure, gout, coronary artery disease, congestive heart failure, severe liver disease or a history of kidney surgery.
• the sense and antisense strands are independently 21 to 24 nucleotides in length.
• the sense and antisense strands can be either the same length or different lengths.
• the HBV RNAi agents disclosed herein have been designed to include antisense strand sequences that are at least partially complementary to a sequence in the HBV genome that is conserved across the majority of known serotypes of HBV.
• the RNAi agents described herein upon delivery to a cell expressing HBV, inhibit the expression of one or more HBV genes in vivo or in vitro.
• the first and the second RNAi agents disclosed herein comprise any of the sequences in Table 1.
• one of the RNAi agents comprising the RNAi component has is represented by the following structure (antisense strand comprising SEQ ID NO: 8 and a sense strand comprising SEQ ID NO: 16), shown as the sodium salt:
• one of the RNAi agents comprising the RNAi component has is represented by the following structure (antisense strand comprising SEQ ID NO: 8 and a sense strand comprising SEQ ID NO: 18), shown as the sodium salt:
• HBV RNAi agents when added to pharmaceutically acceptable excipients and/or adjuvants, can be packaged into kits, containers, packs, or dispensers.
• the pharmaceutical compositions described herein can be packaged in pre-filled syringes or vials.
• the first RNAi agent to the second RNAi agent are administered in a combined amount of about 25 mg, about 50 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, or about 400 mg per dose administration.
• the first RNAi agent and the second RNAi agent are administered in a combined amount of about 50 mg, about 75 mg, about 100 mg, or about 125 mg per dose administration.
• the first RNAi agent and the second RNAi agent are administered in a combined amount of about 25 mg, about 35 mg, about 40 mg, or about 200 mg per dose administration.
• Methods according to embodiments of the application further comprises administering to the subject in need thereof another immunogenic agent (such as another innate immune modulator or a therapeutic vaccine) or another antiviral agent against HBV (such as a nucleoside analog or other direct antiviral compound) in combination with a composition of the application.
• another immunogenic agent such as another innate immune modulator or a therapeutic vaccine
• another antiviral agent against HBV such as a nucleoside analog or other direct antiviral compound
• a combination of the application further comprises at least one other active ingredient, such as one or more from among antiviral agents, immunomodulatory agents, and Capsid Assembly Modulators (CAMs), e.g., in the form of small molecule(s), antibody(ies), polypeptide(s), protein(s) or nucleic acid(s), including, but not limited to, one or more from among immune checkpoint inhibitors (e.g., anti-PD-1, anti-TIM-3, etc.), other toll-like receptor agonists, RIG- I agonists, IL-15 superagonists (Altor Bioscience), mutant IRF3 and IRF7 genetic adjuvants, STING agonists (Aduro), FLT3L genetic adjuvant, IL-12 genetic adjuvant, IL-7-hyFc; CAR-T which bind HBV env (S-CAR cells); CAM; cccDNA inhibitors, Interferon alpha receptor ligands.
• CAMs Capsid Assembly Modul
• a combination of the application further comprises one or more other HBV antiviral agents, such as, an HBV polymerase inhibitor (e.g., entecavir and tenofovir); Immunomodulators; Toll-like receptor 7 modulators; Toll-like receptor 8 modulators; Toll-like receptor 3 modulators; Hyaluronidase inhibitors; Modulators of IL-10; HBsAg inhibitors; Toll like receptor 9 modulators; Cyclophilin inhibitors; HBV Prophylactic vaccines; HBV Therapeutic vaccines; HBV viral entry inhibitors; antisense oligonucleotides targeting viral mRNA, more particularly anti-HBV antisense oligonucleotides; short interfering RNAs (siRNA), more particularly anti-HBV siRNA; endonuclease modulators; inhibitors of ribonucleotide reductase; HBV E antigen inhibitors; HBV antibodies targeting the surface antigens of the hepatit
• HBV polymerase inhibitor
• the RNAi component comprises: (i) a first RNAi agent comprising: an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, and a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15; and (ii) a second RNAi agent comprising: an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:8 and SEQ ID NO:9, and a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO
• two RNAi agents are administered at a combined dose of 25-400 mg per dose administration.
• two RNAi agents are administered at a combined dose of 25-400 mg, and the first RNAi agent is administered with the second RNAi agent at a ratio of 1:1.
• the dose of each of the first and second RNAi agents is in an amount of about 12 mg for a combined dose of about 25 mg.
• the dose of each of the first and second RNAi agents is in an amount of about 17 mg for a combined dose of about 35 mg.
• the dose of each of the first and second RNAi agents is in an amount of about 20 mg for a combined dose of about 40 mg.
• the first RNAi agent and the second RNAi agent are administered for a duration of about 1-12 months. In some embodiments, the first RNAi agent and the second RNAi agent are administered for a duration of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months or at least about 12 months. In some embodiments, the first RNAi agent and the second RNAi agent are administered for a duration of about 1-18 weeks.
• RNAi component comprising a first RNAi agent comprising an antisense strand comprising SEQ ID NO: 2 and a sense strand comprising SEQ ID NO: 11 and a second RNAi agent comprising an antisense strand comprising SEQ ID NO: 8 and a sense strand comprising SEQ ID NO: 16 (with the first RNAi agent and the second RNAi agent present in a molar ratio of 2:1) in men and women between 18 to 80 years of age, inclusive, with moderate and severe renal impairment ESRD, not on dialysis with no other major co-morbidity and healthy participants with normal renal function as the control group.
• the design of the study follows current recommendations from the US FDA guidance (FDA Guidance 2020) and the EMA guideline (EMA Guideline 2015) on the evaluation of PK of medicinal products in participants with impaired renal function.
• the study will consist of a screening phase (within 28 days before study drug administration); an open-label treatment phase (Day -1 until Day 4) with single-dose treatment on Day 1 and 4 days of PK sampling, and EOS/follow-up assessments on Day 14. Participants who withdraw from the study before completion of the planned PK assessments will have the EOS assessments performed before discharge. The total study length for an individual participant will be approximately 42 days (including screening and EOS/follow-up assessments).
• Non-smoker or light smoker who smokes no more than 10 cigarettes, or 2 cigars, or 2 pipes of tobacco per day; willing to limit smoking for the period of confinement to 4 cigarettes or 1 cigar or 1 pipe of tobacco per day.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Genetics & Genomics (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Wood Science & Technology (AREA)
• General Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Biotechnology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Plant Pathology (AREA)
• Microbiology (AREA)
• Biophysics (AREA)
• Physics & Mathematics (AREA)
• Biochemistry (AREA)
• Virology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=82703082

Family Applications (1)

Country Status (7)

Cited By (1)

Citations (13)

• 2022
  • 2022-07-07 JP JP2024501166A patent/JP2024527380A/ja active Pending
  • 2022-07-07 CA CA3224600A patent/CA3224600A1/en active Pending
  • 2022-07-07 CN CN202280048358.4A patent/CN117616121A/zh active Pending
  • 2022-07-07 WO PCT/IB2022/056278 patent/WO2023281434A1/en not_active Ceased
  • 2022-07-07 US US18/577,450 patent/US20240336921A1/en active Pending
  • 2022-07-07 EP EP22747759.3A patent/EP4367241A1/en active Pending
  • 2022-07-08 TW TW111125691A patent/TW202323525A/zh unknown

Patent Citations (17)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events